HRP20050119A2 - Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals - Google Patents
Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticalsInfo
- Publication number
- HRP20050119A2 HRP20050119A2 HR20050119A HRP20050119A HRP20050119A2 HR P20050119 A2 HRP20050119 A2 HR P20050119A2 HR 20050119 A HR20050119 A HR 20050119A HR P20050119 A HRP20050119 A HR P20050119A HR P20050119 A2 HRP20050119 A2 HR P20050119A2
- Authority
- HR
- Croatia
- Prior art keywords
- formula
- acylated
- heteroaryl
- compounds
- enzyme
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Prikazani izum se odnosi na acilirane, heteroaril-kondenzirane cikloalkenilamin formule I, (I) u kojoj A, R1, R2, R3, R4, R5 i n imaju značenja naznačena u patentnim zahtjevima. Spojevi formule I su vrijedni farmakološki aktivni spojevi koji su korisni u liječenju raznih bolesnih stanja uključujućikardivaskularne poremećaje kao što su arteroskleroza, tromboza, koronarna arterijska bolest, hipertenzija i kardijalna insuficijencija. Reguliraju u ranijim koracima ekspresiju enzima endotelne dušikov oksid (NO) sintetaze i mogu se primjenili kod stanja u kojima je poželjna veća ekspresija navedenog enzima ili veća razina NO ili normalizacija smanjene količine NO. Izum se osim toga odnosi na postupke priprave spojeva formule T, njihovu uporabu,posebice kao aktivnih sastojaka farmaceutika, i farmaceutske pripravke koji ih sadrže.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02017586A EP1388342A1 (en) | 2002-08-07 | 2002-08-07 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
| PCT/EP2003/008103 WO2004014372A1 (en) | 2002-08-07 | 2003-07-24 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20050119A2 true HRP20050119A2 (en) | 2006-05-31 |
Family
ID=30129194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20050119A HRP20050119A2 (en) | 2002-08-07 | 2005-02-04 | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP1388342A1 (hr) |
| JP (1) | JP4608315B2 (hr) |
| KR (1) | KR101061727B1 (hr) |
| CN (1) | CN100337626C (hr) |
| AR (1) | AR040790A1 (hr) |
| AT (1) | ATE524178T1 (hr) |
| AU (1) | AU2003251466B2 (hr) |
| BR (1) | BR0313240A (hr) |
| CA (1) | CA2494302C (hr) |
| DK (1) | DK1534277T3 (hr) |
| ES (1) | ES2373651T3 (hr) |
| HK (1) | HK1079427A1 (hr) |
| HR (1) | HRP20050119A2 (hr) |
| IL (1) | IL166494A (hr) |
| MA (1) | MA27331A1 (hr) |
| ME (1) | MEP25808A (hr) |
| MX (1) | MXPA05000833A (hr) |
| MY (1) | MY140840A (hr) |
| NO (1) | NO330011B1 (hr) |
| NZ (1) | NZ538090A (hr) |
| PL (1) | PL212119B1 (hr) |
| PT (1) | PT1534277E (hr) |
| RS (1) | RS52385B (hr) |
| RU (1) | RU2338743C2 (hr) |
| TW (1) | TWI328582B (hr) |
| WO (1) | WO2004014372A1 (hr) |
| ZA (1) | ZA200410274B (hr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004042607A1 (de) | 2004-09-03 | 2006-03-09 | Bayer Healthcare Ag | Substituierte Phenylaminothiazole und ihre Verwendung |
| EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| EP1741708A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals |
| DE102006042143A1 (de) | 2006-09-08 | 2008-03-27 | Bayer Healthcare Aktiengesellschaft | Neue substituierte Bipyridin-Derivate und ihre Verwendung |
| EP1905764A1 (en) | 2006-09-30 | 2008-04-02 | Sanofi-Aventis | Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals |
| EP1923062A1 (en) | 2006-11-16 | 2008-05-21 | sanofi-aventis | Imidazo[2,1-b]thiazoles and their use as pharmaceuticals |
| DE102006056740A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung |
| DE102006056739A1 (de) | 2006-12-01 | 2008-06-05 | Bayer Healthcare Ag | Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| EP1939180A1 (en) | 2006-12-20 | 2008-07-02 | sanofi-aventis | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase |
| EP1939181A1 (en) | 2006-12-27 | 2008-07-02 | sanofi-aventis | Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase |
| EP1964840A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]pyridines and their use as pharmaceuticals |
| EP1964841A1 (en) | 2007-02-28 | 2008-09-03 | sanofi-aventis | Imidazo[1,2-a]azine and their use as pharmaceuticals |
| DE102007035367A1 (de) | 2007-07-27 | 2009-01-29 | Bayer Healthcare Ag | Substituierte Aryloxazole und ihre Verwendung |
| DE102007036076A1 (de) | 2007-08-01 | 2009-02-05 | Bayer Healthcare Aktiengesellschaft | Dipeptoid-Produgs und ihre Verwendung |
| DE102007061764A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Anellierte Cyanopyridine und ihre Verwendung |
| DE102007061763A1 (de) | 2007-12-20 | 2009-06-25 | Bayer Healthcare Ag | Substituierte azabicyclische Verbindungen und ihre Verwendung |
| DE102008013587A1 (de) | 2008-03-11 | 2009-09-17 | Bayer Schering Pharma Aktiengesellschaft | Heteroaryl-substituierte Dicyanopyridine und ihre Verwendung |
| WO2009143992A1 (de) | 2008-05-29 | 2009-12-03 | Bayer Schering Pharma Aktiengesellschaft | 2-alkoxy-substituierte dicyanopyridine und ihre verwendung |
| BRPI0918502A2 (pt) * | 2008-09-02 | 2015-12-01 | Sanofi Aventis | aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos |
| DE102008062567A1 (de) | 2008-12-16 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | Dipeptoid-Prodrugs und ihre Verwendung |
| CN101759683B (zh) * | 2008-12-25 | 2011-12-28 | 哈尔滨誉衡药业股份有限公司 | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 |
| DE102009006602A1 (de) | 2009-01-29 | 2010-08-05 | Bayer Schering Pharma Aktiengesellschaft | Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs |
| DE102010030688A1 (de) | 2010-06-30 | 2012-01-05 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Dicyanopyridine und ihre Verwendung |
| US20120058983A1 (en) | 2010-09-02 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension |
| RU2545758C1 (ru) * | 2014-03-20 | 2015-04-10 | Общество с ограниченной ответственностью "Алион" | Бициклические пиримидины или их фармацевтически приемлемые соли-активаторы антиоксидантной программы и их применение в качестве цитопротекторов |
| US10752640B2 (en) | 2014-08-01 | 2020-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
| GB201601301D0 (en) * | 2016-01-25 | 2016-03-09 | Takeda Pharmaceutical | Novel compounds |
| KR20200094734A (ko) | 2017-09-22 | 2020-08-07 | 주빌런트 에피파드 엘엘씨 | Pad 억제제로서의 헤테로사이클릭 화합물 |
| DK3697785T3 (da) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Imidazo-pyridine forbindelser som pad-inhibitorer |
| AU2018362046B2 (en) | 2017-11-06 | 2023-04-13 | Jubilant Prodel LLC | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
| CA3083374A1 (en) | 2017-11-24 | 2019-05-31 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
| AU2019234185A1 (en) | 2018-03-13 | 2020-10-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08325234A (ja) * | 1995-05-30 | 1996-12-10 | Yamanouchi Pharmaceut Co Ltd | 安息香酸誘導体又はその塩 |
| JP3013989B2 (ja) * | 1998-03-26 | 2000-02-28 | 日本たばこ産業株式会社 | アミド誘導体及びノシセプチンアンタゴニスト |
| WO1999048492A1 (fr) * | 1998-03-26 | 1999-09-30 | Japan Tobacco Inc. | Derives d'amide et antagonistes de nociceptine |
| WO2001068652A1 (en) * | 2000-03-17 | 2001-09-20 | Novo Nordisk A/S | Condensed imidazoles as histamine h3 receptor ligands |
| AR035431A1 (es) * | 2001-02-13 | 2004-05-26 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
| PE20020856A1 (es) * | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| TWI241190B (en) * | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| TWI243164B (en) * | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
-
2002
- 2002-08-07 EP EP02017586A patent/EP1388342A1/en not_active Withdrawn
-
2003
- 2003-07-24 WO PCT/EP2003/008103 patent/WO2004014372A1/en active Application Filing
- 2003-07-24 ME MEP-258/08A patent/MEP25808A/hr unknown
- 2003-07-24 PL PL373279A patent/PL212119B1/pl not_active IP Right Cessation
- 2003-07-24 RU RU2005106292/04A patent/RU2338743C2/ru not_active IP Right Cessation
- 2003-07-24 MX MXPA05000833A patent/MXPA05000833A/es active IP Right Grant
- 2003-07-24 ES ES03784055T patent/ES2373651T3/es not_active Expired - Lifetime
- 2003-07-24 BR BR0313240-4A patent/BR0313240A/pt not_active IP Right Cessation
- 2003-07-24 AU AU2003251466A patent/AU2003251466B2/en not_active Ceased
- 2003-07-24 DK DK03784055.0T patent/DK1534277T3/da active
- 2003-07-24 AT AT03784055T patent/ATE524178T1/de active
- 2003-07-24 PT PT03784055T patent/PT1534277E/pt unknown
- 2003-07-24 EP EP03784055A patent/EP1534277B1/en not_active Expired - Lifetime
- 2003-07-24 NZ NZ538090A patent/NZ538090A/en not_active IP Right Cessation
- 2003-07-24 CN CNB038191253A patent/CN100337626C/zh not_active Expired - Fee Related
- 2003-07-24 CA CA2494302A patent/CA2494302C/en not_active Expired - Fee Related
- 2003-07-24 RS YU20050097A patent/RS52385B/en unknown
- 2003-07-24 JP JP2004526765A patent/JP4608315B2/ja not_active Expired - Fee Related
- 2003-07-24 KR KR1020057002070A patent/KR101061727B1/ko not_active IP Right Cessation
- 2003-08-05 AR AR20030102803A patent/AR040790A1/es unknown
- 2003-08-05 TW TW092121314A patent/TWI328582B/zh not_active IP Right Cessation
- 2003-08-06 MY MYPI20032964A patent/MY140840A/en unknown
-
2004
- 2004-12-21 ZA ZA200410274A patent/ZA200410274B/en unknown
-
2005
- 2005-01-25 IL IL166494A patent/IL166494A/en not_active IP Right Cessation
- 2005-02-04 MA MA28091A patent/MA27331A1/fr unknown
- 2005-02-04 HR HR20050119A patent/HRP20050119A2/xx not_active Application Discontinuation
- 2005-02-16 NO NO20050830A patent/NO330011B1/no not_active IP Right Cessation
- 2005-12-12 HK HK05111386A patent/HK1079427A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20050119A2 (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
| MEP60508A (hr) | Aciklovani arilcikloalkilamini i njihova upotreba kao farmaceutskih proizvoda | |
| IL166493A0 (en) | Acylamino-substituted heteroaromatic compounds andtheir use as pharmaceuticals | |
| MEP43008A (hr) | Indol-2-karboksamidi kao inhibitori xa faktora | |
| NO20032820D0 (no) | Oksybenzamidderivater som faktor XA inhibitorer | |
| HUP0204235A2 (hu) | Helyettesített glutárimidek és felhasználásuk IL-12 termelés inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| DE602004028367D1 (de) | Neue indolderivate als faktor xa-inhibitoren | |
| MX2008000019A (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o ciclico, y su uso como productos farmaceuticos. | |
| CA2340405A1 (en) | Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same | |
| DE602004020761D1 (de) | INDAZOLDERIVATE ALS FAKTOR Xa-INHIBITOREN | |
| NO20025810D0 (no) | Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse | |
| MXPA05011267A (es) | Derivados de la triaza-y tetraaza-antracenodiona, su preparacion y su uso como productos farmaceuticos. | |
| MEP54708A (en) | N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them | |
| BR9911942B1 (pt) | "n-arilamidas de ácido sulfonilaminocarboxílico como ativadores da ciclasse de guanilato e composições farmacêuticas contendo as mesmas" | |
| MEP57708A (hr) | Inhibitori faktora viia | |
| CY1109545T1 (el) | Συνθεση της (r) και (s)-αμινοκαρνιτινης και παραγωγων που προκυπτουν απο to d- και l- ασπαρτικο οξυ | |
| ATE255565T1 (de) | Substituierte 4-amino-2-aryltetrahydrochinazoline,deren herstellung, deren verwendung und diese enthaltende pharmazeutische zusammenstellungen | |
| DE602004013577D1 (de) | TRIAZOLDERIVATE ALS FAKTOR-Xa-INHIBITOREN | |
| NO995594L (no) | Nye substituerte heterocykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasoeytiske sammensetninger inneholdende dem | |
| MX2008000044A (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador saturado, y su uso como agentes farmaceuticos. | |
| DE69402004D1 (de) | Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen | |
| DE69418110T2 (de) | N-Heteroaryl substituierte Propanamid-Derivate brauchbar zur Behandlung cardiovascularer Krankheiten | |
| TW200716620A (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors | |
| IL139317A0 (en) | Benzimdazole and benzoxazole derivatives and pharmaceutical compositions contining the same | |
| UA48064A1 (uk) | Етиловий ефір 2-сульфамоїлмалонанілової кислоти, який проявляє протизапальну активність |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20120606 Year of fee payment: 10 |
|
| OBST | Application withdrawn |